ACT Laboratories Acquires CDX Analytics

ACT Genomics Acquires MC Diagnostics

August 10, 2021

Medical Devices

Taiwan-based precision medicine company ACT Genomics has acquired North Wales–headquartered molecular diagnostics specialist MC Diagnostics (MCD). The deal gives ACT Genomics access to MCD’s ALDAS microarray platform and point-of-care testing capabilities, supporting ACT’s expansion into Europe and development of additional genechip-based diagnostic products.

SC Labs Acquires C4 Laboratories

April 24, 2023

Healthcare Services

SC Labs, a leading U.S. cannabis and hemp testing company headquartered in Santa Cruz, California, has acquired C4 Laboratories of Scottsdale, Arizona. The acquisition expands SC Labs' licensed and accredited footprint to five states and adds C4's advanced cannabis testing capabilities to SC Labs' national testing and compliance platform.

BioAgilytix Acquires Cambridge Biomedical

November 4, 2019

Healthcare Services

BioAgilytix, a GHO Capital portfolio company, has acquired Cambridge Biomedical, a Cambridge, Massachusetts–based clinical research organisation specializing in large-molecule bioanalysis. The deal expands BioAgilytix's laboratory capacity and capabilities (including CLIA/CAP/GLP capabilities and PCR/molecular suites), broadens its geographic footprint into the Boston/Cambridge biotech cluster, and strengthens its cell- and gene-therapy bioanalytical offerings.

Agno Pharma Acquires Actylis Eugene (Legacy Cascade Chemistry) in Eugene, Oregon

January 15, 2026

Pharmaceuticals

Agno Pharma has acquired Actylis Eugene, the legacy Cascade Chemistry manufacturing asset in Eugene, Oregon, expanding Agno's U.S. cGMP API development and manufacturing footprint. The site includes a 16,000 sq. ft. R&D lab and a newly constructed 30,000 sq. ft. GMP manufacturing facility, enhancing Agno's capabilities to support biotech and pharmaceutical clients from early-phase through commercial API production.

Cresco Labs Acquires Cultivate in Massachusetts

September 3, 2021

Retail

Cresco Labs has closed its acquisition of Cultivate, a vertically integrated Massachusetts cannabis operator with three dispensaries and approximately 42,000 square feet of active cultivation canopy. The deal increases Cresco's in-state cultivation to ~64,000 square feet and expands its retail footprint in Massachusetts as part of a strategy to deepen presence in large, attractive state markets.

CV Sciences Acquires Extract Labs

November 21, 2024

Consumer Products

CV Sciences, Inc. entered into a definitive agreement to acquire Extract Labs, Inc., a manufacturer and distributor of premium cannabinoid products, for $400,000 in cash plus $1,000,000 in CV Sciences shares at closing. Additional contingent consideration of up to $600,000 in CV Sciences shares may be earned based on Extract Labs revenue targets post-closing, which is expected in Q1 2025.